Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26616036 | 0.91 | EGFR (0.53) | SMN1; SMN2KDM4EALDH1A1EGFRMAOB | |
| SCHEMBL7805490 | 0.88 | KMT2A (0.53) | SMN1; SMN2KDM4EALDH1A1EGFRMAPT | |
| SCHEMBL26731300 | 0.84 | HTT (0.48) | SMN1; SMN2KDM4EALDH1A1MAOBMAPT | |
| SCHEMBL26607243 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EMAPTLMNAHTT | |
| SCHEMBL12737235 | 0.82 | KLK7 (0.46) | SMN1; SMN2KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL26731827 | 0.82 | HTT (0.44) | SMN1; SMN2MAPTMEN1LMNAKMT2A | |
| SCHEMBL15578467 | 0.80 | ALDH1A1 (0.59) | SMN1; SMN2KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL4725521 | 0.80 | MAOB (0.48) | SMN1; SMN2KDM4EALDH1A1EGFRMAOB | |
| SCHEMBL995831 | 0.80 | MAPT (0.44) | SMN1; SMN2KDM4EALDH1A1MAOBMAPT | |
| SCHEMBL26607285 | 0.79 | PDGFRB (0.43) | SMN1; SMN2KDM4EALDH1A1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1618789-A | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM CA LTD (CA) | 2005-05-25 | — | — | CN | disclosed |
| CN-1177861-C | Macrocyclic Peptides Effective Against Hepatitis C Virus | ���ָ����Ӣ��ķ���ô�����˾ | 2004-12-01 | — | — | CN | disclosed |
| EP-1169339-B1 | MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-09-29 | — | — | EP | disclosed |
| EP-1437362-A1 | Macrocyclic peptides inhibiting the hepatitis C virus ns3 protease | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-14 | — | — | EP | disclosed |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-01-01 | — | — | US | disclosed |
| US-6608027-B1 | Macrocyclic small peptides of low molecular weight that are inhibitory to NS3 protease of hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2003-08-19 | — | — | US | disclosed |
| CN-1346365-A | Macrocyclic Peptides Effective Against Hepatitis C Virus | BOEHRINGER INGELHEIM CA LTD (CA) | 2002-04-24 | — | — | CN | disclosed |
| EP-1169339-A1 | MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000059929-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | VIP, FURIN, RNASE1 | SMN1; SMN2 2976/4885KDM4E 3584/4885ALDH1A1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.